15.5-day G7 integrated continuous glucose monitor in adults with diabetes shows positive results
In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...
INHALE-3 extension study: Inhaled technosphere insulin plus insulin degludec maintains glycemic control
A new study in the journal Diabetes Technology & Therapeutics evaluated the effects of a regimen of inhaled technosphere ...
EurekAlert!4d
Results of the INHALE-3 extension study: inhaled technosphere insulin plus insulin degludec in T1D
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its ...
Study suggests inhaled technosphere insulin could be considered as an option for adults with type 1 diabetes
A study in the journal Diabetes Technology & Therapeutics (DTT) concludes that inhaled technosphere insulin (TI-Afrezza) ...
Healio4d
Inhaled insulin lowers HbA1c at 30 weeks in adults with type 1 diabetes
Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c ...
EurekAlert!6d
Evaluation of inhaled technosphere insulin plus insulin degludec for adults with type 1 diabetes
A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) concluded that inhaled technosphere insulin ...
Daily18d
Biocon Biologics, Civica join hands to expand Insulin Aspart access in US
Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug substance to Civica, Inc., who will use the drug substance to produce Insulin Aspart drug product, a rapid-acting ...
Pharmabiz18d
Biocon Biologics and Civica collaborate to expand insulin aspart access in the US
Under the terms of the agreement, Biocon Biologics will supply insulin aspart drug substance to Civica, who will use the drug substance to produce insulin aspart drug product, a rapid-acting insulin ...
BioSpace19d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics and Civica announce agreement to expand access and affordability of Insulin Aspart in the U.S. Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug ...
tradebrains19d
Pharma stock jumps after partnering with Civica to expand Insulin Aspart access in US
The shares of the biopharmaceutical company jumped up to 2 percent after the company announced a collaboration to expand Insulin Aspart access in the United States. The shares of Biocon Ltd have seen ...
Morningstar19d
Biocon Biologics and Civica, Inc. Collaborate to Expand Insulin Aspart Access in the United States
Biocon Biologics and Civica announce agreement to expand access and affordability of Insulin Aspart in the U.S. Under the terms of the agreement, Biocon Biologics will supply Insulin Aspart drug ...